Lyell Immunopharma (LYEL) Enterprise Value (2020 - 2026)

Lyell Immunopharma (LYEL) has 7 years of Enterprise Value data on file, last reported at -$254.0 million in Q1 2026.

• For the quarter ending Q1 2026, Enterprise Value rose 15.66% year-over-year to -$254.0 million; the trailing twelve-month figure through Mar 2026 stood at -$254.0 million (up 15.66% YoY), and the FY2025 full-year result was -$247.2 million, up 33.28% from the prior year.
• Enterprise Value declined to -$254.0 million in Q1 2026, from -$247.2 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$247.2 million in Q4 2025 to a low of -$655.6 million in Q2 2022.
• A 5-year average of -$477.4 million and a median of -$526.3 million in 2024 frame the typical range for Enterprise Value.
• Across the five-year window, Enterprise Value slumped 151.22% in 2022 and jumped 43.64% in 2025, its largest moves.
• Tracing LYEL's Enterprise Value over 5 years: stood at -$640.2 million in 2022, then grew by 14.67% to -$546.2 million in 2023, then soared by 32.17% to -$370.5 million in 2024, then surged by 33.28% to -$247.2 million in 2025, then fell by 2.75% to -$254.0 million in 2026.
• Business Quant data shows LYEL's Enterprise Value at -$254.0 million in Q1 2026, -$247.2 million in Q4 2025, and -$319.6 million in Q3 2025.